STOCK TITAN

[DEFA14A] VINCERX PHARMA INC Additional Proxy Soliciting Materials

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
DEFA14A
Rhea-AI Filing Summary

Vincerx Pharma announced the adjournment of its Special Meeting of Stockholders to July 16, 2025, seeking additional time to secure votes for the company's Dissolution Proposal. The meeting, originally scheduled for June 18, 2025, is critical for stockholder interests.

Key aspects of the Dissolution Proposal include:

  • Potential preservation of stockholder distributions by reducing ongoing public company operating costs
  • Opportunity for U.S. stockholders to recognize potential tax benefits through capital loss
  • Risk that further delays could reduce or eliminate available funds for stockholder distributions

Acting CEO Dr. Raquel Izumi emphasized the urgency of stockholder approval, noting that delays will increase expenditures and decrease potential distributions. The company has established multiple voting channels including phone (1-877-870-8565) and internet (www.proxyvote.com). The board unanimously recommends voting FOR the Dissolution Proposal to maximize potential stockholder value during the wind-down process.

Vincerx Pharma ha annunciato il rinvio della sua Assemblea Straordinaria degli Azionisti al 16 luglio 2025, per ottenere più tempo utile a raccogliere voti a favore della Proposta di Scioglimento della società. L'incontro, originariamente previsto per il 18 giugno 2025, è fondamentale per gli interessi degli azionisti.

Gli aspetti principali della Proposta di Scioglimento includono:

  • Possibile conservazione delle distribuzioni agli azionisti riducendo i costi operativi di una società pubblica in attività
  • Opportunità per gli azionisti statunitensi di beneficiare fiscalmente di eventuali perdite in conto capitale
  • Rischio che ulteriori ritardi possano ridurre o azzerare i fondi disponibili per le distribuzioni agli azionisti

La CEO ad interim, Dott.ssa Raquel Izumi, ha sottolineato l'urgenza dell'approvazione da parte degli azionisti, evidenziando che i ritardi aumenteranno le spese e diminuiranno le potenziali distribuzioni. La società ha attivato diversi canali di voto, inclusi telefono (1-877-870-8565) e internet (www.proxyvote.com). Il consiglio di amministrazione raccomanda all'unanimità di votare SI alla Proposta di Scioglimento per massimizzare il valore potenziale per gli azionisti durante il processo di liquidazione.

Vincerx Pharma anunció el aplazamiento de su Junta Especial de Accionistas al 16 de julio de 2025, buscando más tiempo para asegurar los votos a favor de la Propuesta de Disolución de la empresa. La reunión, originalmente programada para el 18 de junio de 2025, es crucial para los intereses de los accionistas.

Los aspectos clave de la Propuesta de Disolución incluyen:

  • Posible preservación de las distribuciones a accionistas mediante la reducción de los costos operativos continuos de la empresa pública
  • Oportunidad para que los accionistas estadounidenses reconozcan beneficios fiscales potenciales a través de pérdidas de capital
  • Riesgo de que más retrasos reduzcan o eliminen los fondos disponibles para las distribuciones a accionistas

La CEO interina, Dra. Raquel Izumi, enfatizó la urgencia de la aprobación de los accionistas, señalando que los retrasos incrementarán los gastos y disminuirán las distribuciones potenciales. La empresa ha establecido múltiples canales de votación, incluyendo teléfono (1-877-870-8565) e internet (www.proxyvote.com). La junta recomienda unánimemente votar A FAVOR de la Propuesta de Disolución para maximizar el valor potencial para los accionistas durante el proceso de liquidación.

Vincerx Pharma는 회사의 해산 제안에 대한 투표 확보를 위해 시간을 더 확보하고자 특별 주주총회를 2025년 7월 16일로 연기했다고 발표했습니다. 원래 2025년 6월 18일로 예정되었던 이 회의는 주주 이익에 매우 중요한 행사입니다.

해산 제안의 주요 내용은 다음과 같습니다:

  • 공공 기업의 지속적인 운영비용을 줄여 주주 배당금을 보존할 가능성
  • 미국 주주들이 자본 손실을 통한 잠재적 세금 혜택을 인식할 기회
  • 추가 지연 시 주주 배당금으로 사용할 수 있는 자금이 감소하거나 없어질 위험

임시 CEO인 라켈 이즈미 박사는 주주 승인 시급성을 강조하며, 지연이 비용을 증가시키고 배당금을 줄일 것이라고 언급했습니다. 회사는 전화(1-877-870-8565)와 인터넷(www.proxyvote.com) 등 다양한 투표 경로를 마련했습니다. 이사회는 해산 제안에 찬성 투표할 것을 만장일치로 권고하여 청산 과정에서 주주 가치를 극대화하려 합니다.

Vincerx Pharma a annoncé le report de son Assemblée Spéciale des Actionnaires au 16 juillet 2025, afin d'obtenir plus de temps pour recueillir des votes en faveur de la Proposition de Dissolution de la société. La réunion, initialement prévue le 18 juin 2025, est cruciale pour les intérêts des actionnaires.

Les points clés de la Proposition de Dissolution sont :

  • Préservation potentielle des distributions aux actionnaires en réduisant les coûts opérationnels continus d'une société cotée
  • Opportunité pour les actionnaires américains de bénéficier d'avantages fiscaux potentiels via une perte en capital
  • Risque que de nouveaux retards réduisent ou éliminent les fonds disponibles pour les distributions aux actionnaires

La directrice générale par intérim, Dr Raquel Izumi, a souligné l'urgence de l'approbation des actionnaires, notant que les retards augmenteraient les dépenses et diminueraient les distributions potentielles. La société a mis en place plusieurs moyens de vote, notamment par téléphone (1-877-870-8565) et internet (www.proxyvote.com). Le conseil d'administration recommande à l'unanimité de voter POUR la Proposition de Dissolution afin de maximiser la valeur potentielle pour les actionnaires durant le processus de liquidation.

Vincerx Pharma gab die Verschiebung seiner außerordentlichen Hauptversammlung der Aktionäre auf den 16. Juli 2025 bekannt, um zusätzliche Zeit zu gewinnen, um Stimmen für den Auflösungsantrag des Unternehmens zu sichern. Die ursprünglich für den 18. Juni 2025 geplante Versammlung ist entscheidend für die Interessen der Aktionäre.

Wesentliche Punkte des Auflösungsantrags sind:

  • Mögliche Erhaltung der Ausschüttungen an Aktionäre durch Reduzierung der laufenden Betriebskosten eines börsennotierten Unternehmens
  • Chance für US-Aktionäre, potenzielle Steuervorteile durch Kapitalverluste zu realisieren
  • Risiko, dass weitere Verzögerungen verfügbare Mittel für Ausschüttungen an Aktionäre verringern oder eliminieren könnten

Die amtierende CEO Dr. Raquel Izumi betonte die Dringlichkeit der Zustimmung der Aktionäre und wies darauf hin, dass Verzögerungen die Ausgaben erhöhen und potenzielle Ausschüttungen verringern würden. Das Unternehmen hat mehrere Abstimmungskanäle eingerichtet, darunter Telefon (1-877-870-8565) und Internet (www.proxyvote.com). Der Vorstand empfiehlt einstimmig, FÜR den Auflösungsantrag zu stimmen, um den potenziellen Wert für die Aktionäre während des Abwicklungsprozesses zu maximieren.

Positive
  • None.
Negative
  • Company seeking stockholder approval for complete liquidation and dissolution, indicating business failure and end of operations
  • Ongoing delays in dissolution approval are depleting remaining cash reserves through continued operating costs, potentially eliminating any stockholder distributions
  • Management indicates significant uncertainty about whether any cash will be available for distribution to stockholders after dissolution
  • Company may need to seek bankruptcy court protection, as mentioned in risk factors
  • Special meeting had to be adjourned due to insufficient stockholder votes, suggesting potential complications in dissolution process

Vincerx Pharma ha annunciato il rinvio della sua Assemblea Straordinaria degli Azionisti al 16 luglio 2025, per ottenere più tempo utile a raccogliere voti a favore della Proposta di Scioglimento della società. L'incontro, originariamente previsto per il 18 giugno 2025, è fondamentale per gli interessi degli azionisti.

Gli aspetti principali della Proposta di Scioglimento includono:

  • Possibile conservazione delle distribuzioni agli azionisti riducendo i costi operativi di una società pubblica in attività
  • Opportunità per gli azionisti statunitensi di beneficiare fiscalmente di eventuali perdite in conto capitale
  • Rischio che ulteriori ritardi possano ridurre o azzerare i fondi disponibili per le distribuzioni agli azionisti

La CEO ad interim, Dott.ssa Raquel Izumi, ha sottolineato l'urgenza dell'approvazione da parte degli azionisti, evidenziando che i ritardi aumenteranno le spese e diminuiranno le potenziali distribuzioni. La società ha attivato diversi canali di voto, inclusi telefono (1-877-870-8565) e internet (www.proxyvote.com). Il consiglio di amministrazione raccomanda all'unanimità di votare SI alla Proposta di Scioglimento per massimizzare il valore potenziale per gli azionisti durante il processo di liquidazione.

Vincerx Pharma anunció el aplazamiento de su Junta Especial de Accionistas al 16 de julio de 2025, buscando más tiempo para asegurar los votos a favor de la Propuesta de Disolución de la empresa. La reunión, originalmente programada para el 18 de junio de 2025, es crucial para los intereses de los accionistas.

Los aspectos clave de la Propuesta de Disolución incluyen:

  • Posible preservación de las distribuciones a accionistas mediante la reducción de los costos operativos continuos de la empresa pública
  • Oportunidad para que los accionistas estadounidenses reconozcan beneficios fiscales potenciales a través de pérdidas de capital
  • Riesgo de que más retrasos reduzcan o eliminen los fondos disponibles para las distribuciones a accionistas

La CEO interina, Dra. Raquel Izumi, enfatizó la urgencia de la aprobación de los accionistas, señalando que los retrasos incrementarán los gastos y disminuirán las distribuciones potenciales. La empresa ha establecido múltiples canales de votación, incluyendo teléfono (1-877-870-8565) e internet (www.proxyvote.com). La junta recomienda unánimemente votar A FAVOR de la Propuesta de Disolución para maximizar el valor potencial para los accionistas durante el proceso de liquidación.

Vincerx Pharma는 회사의 해산 제안에 대한 투표 확보를 위해 시간을 더 확보하고자 특별 주주총회를 2025년 7월 16일로 연기했다고 발표했습니다. 원래 2025년 6월 18일로 예정되었던 이 회의는 주주 이익에 매우 중요한 행사입니다.

해산 제안의 주요 내용은 다음과 같습니다:

  • 공공 기업의 지속적인 운영비용을 줄여 주주 배당금을 보존할 가능성
  • 미국 주주들이 자본 손실을 통한 잠재적 세금 혜택을 인식할 기회
  • 추가 지연 시 주주 배당금으로 사용할 수 있는 자금이 감소하거나 없어질 위험

임시 CEO인 라켈 이즈미 박사는 주주 승인 시급성을 강조하며, 지연이 비용을 증가시키고 배당금을 줄일 것이라고 언급했습니다. 회사는 전화(1-877-870-8565)와 인터넷(www.proxyvote.com) 등 다양한 투표 경로를 마련했습니다. 이사회는 해산 제안에 찬성 투표할 것을 만장일치로 권고하여 청산 과정에서 주주 가치를 극대화하려 합니다.

Vincerx Pharma a annoncé le report de son Assemblée Spéciale des Actionnaires au 16 juillet 2025, afin d'obtenir plus de temps pour recueillir des votes en faveur de la Proposition de Dissolution de la société. La réunion, initialement prévue le 18 juin 2025, est cruciale pour les intérêts des actionnaires.

Les points clés de la Proposition de Dissolution sont :

  • Préservation potentielle des distributions aux actionnaires en réduisant les coûts opérationnels continus d'une société cotée
  • Opportunité pour les actionnaires américains de bénéficier d'avantages fiscaux potentiels via une perte en capital
  • Risque que de nouveaux retards réduisent ou éliminent les fonds disponibles pour les distributions aux actionnaires

La directrice générale par intérim, Dr Raquel Izumi, a souligné l'urgence de l'approbation des actionnaires, notant que les retards augmenteraient les dépenses et diminueraient les distributions potentielles. La société a mis en place plusieurs moyens de vote, notamment par téléphone (1-877-870-8565) et internet (www.proxyvote.com). Le conseil d'administration recommande à l'unanimité de voter POUR la Proposition de Dissolution afin de maximiser la valeur potentielle pour les actionnaires durant le processus de liquidation.

Vincerx Pharma gab die Verschiebung seiner außerordentlichen Hauptversammlung der Aktionäre auf den 16. Juli 2025 bekannt, um zusätzliche Zeit zu gewinnen, um Stimmen für den Auflösungsantrag des Unternehmens zu sichern. Die ursprünglich für den 18. Juni 2025 geplante Versammlung ist entscheidend für die Interessen der Aktionäre.

Wesentliche Punkte des Auflösungsantrags sind:

  • Mögliche Erhaltung der Ausschüttungen an Aktionäre durch Reduzierung der laufenden Betriebskosten eines börsennotierten Unternehmens
  • Chance für US-Aktionäre, potenzielle Steuervorteile durch Kapitalverluste zu realisieren
  • Risiko, dass weitere Verzögerungen verfügbare Mittel für Ausschüttungen an Aktionäre verringern oder eliminieren könnten

Die amtierende CEO Dr. Raquel Izumi betonte die Dringlichkeit der Zustimmung der Aktionäre und wies darauf hin, dass Verzögerungen die Ausgaben erhöhen und potenzielle Ausschüttungen verringern würden. Das Unternehmen hat mehrere Abstimmungskanäle eingerichtet, darunter Telefon (1-877-870-8565) und Internet (www.proxyvote.com). Der Vorstand empfiehlt einstimmig, FÜR den Auflösungsantrag zu stimmen, um den potenziellen Wert für die Aktionäre während des Abwicklungsprozesses zu maximieren.

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 14A

(RULE 14a-101)

SCHEDULE 14AINFORMATION

Proxy Statement Pursuant To Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under§ 240.14a-12

VINCERX PHARMA, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11

 

 
 


[Press release issued June 18, 2025]

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene

Meeting on July 16 , 2025 to Secure Votes Needed to Approve Dissolution Proposal

Failure to approve Dissolution Proposal will reduce or eliminate

any potential distributions to stockholders

San Mateo, California, June 18, 2025 – Vincerx Pharma, Inc. today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the “Dissolution Proposal”), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal.

Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal.

Vincerx’s board of directors unanimously recommends that stockholders vote FOR the Dissolution Proposal and believes that approval of the Dissolution Proposal is extremely important to stockholders for a number of reasons, including the following:

 

   

Preserve Possibility of Distributions. Vincerx is hopeful that cash will be available for distribution to its stockholders. However, further delays in approving the Dissolution Proposal will result in continued public company and other operating costs and expenses - reducing or eliminating what funds could remain for distribution to stockholders. Approving the Dissolution Proposal will allow Vincerx to move forward expeditiously and maximize the likelihood of a distribution to its stockholders.

 

   

Recognize Potential Tax Benefits. U.S. stockholders who receive less than their tax basis in their shares could be eligible to recognize a capital loss for U.S. federal income tax purposes. Timely approval of the Dissolution Proposal will facilitate this recognition.

“We believe it is extremely important that our stockholders vote FOR the Dissolution Proposal,” said Dr. Raquel Izumi, Acting CEO. “We understand the disappointment that all of us who are stockholders and supported the company over the years feel, but approving the Dissolution Proposal at least gives stockholders the possibility of receiving some value for their shares. Delaying approval of the Dissolution Proposal will simply result in the company continuing to incur ongoing operating costs and expenses, which will only reduce or even eliminate the likelihood that there will be any amounts left for distribution to stockholders. We therefore urge all stockholders to vote FOR the Dissolution Proposal before the reconvened meeting on July 16, 2025.”

Every vote matters. Stockholders must ACTIVELY VOTE for their vote to count. Any delay in approving the Dissolution Proposal will result in increased expenditures and reduce the likelihood that amounts will be available for distribution to stockholders.


Voting is quick and simple:

 

   

BY PHONE: Please call Advantage Proxy, Vincerx’s proxy solicitor, toll-free at 1-877-870-8565 between the hours of 9:00 a.m. and 9:00 p.m., Eastern Time, Monday through Friday. You can also contact Advantage Proxy if you have any questions about voting.

 

   

BY INTERNET: Vote by going to www.proxyvote.com and entering the control number on your proxy card or by following the instructions provided by your broker, bank, or other nominee.

Your vote FOR the Dissolution Proposal is very important - please VOTE TODAY.

Additional Information

Information regarding the Dissolution Proposal, including the board of director’s reasons for recommending approval of the Dissolution Proposal, is set forth in the company’s proxy statement and supplements thereto, which have been filed with the Securities and Exchange Commission (“SEC”) and are available at the SEC’s website at www.sec.gov.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws including, but not limited to, statements about the reasons for approving, and the consequences of failing to approve, the Dissolution Proposal; the potential availability of amounts for distribution to stockholders; and the potential tax benefits to stockholders of approving the Dissolution Proposal. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks involved in dissolving, liquidating, and winding down Vincerx’s business and affairs; the timing or amount of distributions, if any, to Vincerx’s stockholders; stockholder approval of the Dissolution Proposal and the timeliness of such approval; the risk that Vincerx may need to seek protection of the bankruptcy court; and the other factors discussed in Vincerx’s reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Vincerx as of the date of this press release. Vincerx undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:

info@vincerx.com

FAQ

Why is VINC holding a Special Meeting of Stockholders on July 16, 2025?

VINC is holding a Special Meeting on July 16, 2025 (adjourned from June 18) to secure stockholder votes for the Dissolution Proposal, which would approve the liquidation and dissolution of the company. The board unanimously recommends voting FOR the proposal to maximize potential distributions to stockholders and minimize ongoing operating costs.

What happens if VINC stockholders don't approve the Dissolution Proposal?

If stockholders don't approve the Dissolution Proposal, VINC will continue to incur public company and operating costs, which will reduce or potentially eliminate any funds that could be distributed to stockholders. The company warns that delays in approval will directly impact the likelihood of stockholder distributions.

What are the potential tax benefits for VINC stockholders from the dissolution?

U.S. stockholders of VINC who receive less than their tax basis in their shares could be eligible to recognize a capital loss for U.S. federal income tax purposes. The timely approval of the Dissolution Proposal will facilitate this tax loss recognition.

How can VINC shareholders vote on the Dissolution Proposal?

VINC shareholders can vote in two ways: 1) By phone - calling Advantage Proxy toll-free at 1-877-870-8565 between 9:00 a.m. and 9:00 p.m. Eastern Time, Monday-Friday, or 2) Online - by visiting www.proxyvote.com and entering their control number or following their broker's instructions.

What risks did VINC disclose regarding the dissolution process?

VINC disclosed several risks including: uncertainty in the timing and amount of potential distributions to stockholders, the possibility of needing bankruptcy court protection, risks involved in dissolving and winding down business operations, and the requirement for timely stockholder approval of the Dissolution Proposal.
Vincerx Pharma Inc

OTC:VINC

VINC Rankings

VINC Latest News

VINC Stock Data

3.54M
5.02M
11.59%
10.77%
8.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO